



## Exelixis Announces June 15 Webcast of Presentation at the Goldman Sachs 31st Annual Global Healthcare Conference

June 10, 2010

SOUTH SAN FRANCISCO, Calif., Jun 10, 2010 (BUSINESS WIRE) --Exelixis, Inc. (NASDAQ: EXEL) announced today that George A. Scangos, PhD, the company's president and chief executive officer, will present at the Goldman Sachs 31st Annual Global Healthcare Conference at 1:20 p.m. PDT / 4:20 p.m. EDT on Tuesday June 15, 2010 in Los Angeles. Dr. Scangos will discuss the company's corporate strategy and development pipeline, and provide a general business update.

The event will be webcast and may be accessed in the Event Calendar page under Investors at <http://www.exelixis.com>.

### About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its biological expertise and integrated research and development capabilities to generate a pipeline of development compounds with significant therapeutic and commercial potential for the treatment of cancer and potentially other serious diseases. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb Company, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, and Daiichi-Sankyo. For more information, please visit the company's web site at <http://www.exelixis.com>.

Exelixis and the Exelixis logo are registered U.S. trademarks.



SOURCE: Exelixis, Inc.

#### *Investor Contacts:*

*Exelixis, Inc.*

*Charles Butler, 650-837-7277*

*Vice President,*

*Investor Relations*

*and Corporate Communications*

[cbutler@exelixis.com](mailto:cbutler@exelixis.com)

*DeDe Sheel, 650-837-8231*

*Associate Director,*

*Investor Relations*

[dsheel@exelixis.com](mailto:dsheel@exelixis.com)